Gilead Sciences | GILD - Stock



Gilead Sciences reported $1.83B in Stock for its fiscal quarter ending in June of 2025.


Stock Change Date
AbbVie USD 4.53B 345M Mar/2025
Agios Pharmaceuticals USD 30.85M 1.24M Jun/2025
ALKERMES USD 191.92M 8.49M Jun/2025
Alnylam Pharmaceuticals USD 71.69M 6.11M Jun/2025
Amgen USD 6.58B 146M Jun/2025
Biogen USD 2.27B 400K Jun/2025
BioMarin Pharmaceutical USD 1.34B 65.32M Jun/2025
Bristol-Myers Squibb USD 2.74B 71M Jun/2025
Eli Lilly USD 11.01B 1.7B Jun/2025
Gilead Sciences USD 1.83B 66M Jun/2025
GlaxoSmithKline GBP 6.07B 72M Jun/2025
Glaxosmithkline 6.07B 403M Jun/2025
Incyte USD 83.42M 19.45M Jun/2025
J&J USD 12.66B 215M Mar/2025
Merck USD 6.6B 405M Jun/2025
Moderna USD 240M 112M Jun/2025
Neurocrine Biosciences USD 56.9M 2.2M Jun/2025
Novartis USD 6.31B 478M Jun/2025
Pfizer USD 11.67B 817M Jun/2025
PTC Therapeutics USD 34.06M 12.39M Jun/2025
Regeneron Pharmaceuticals USD 3.21B 760.7M Jun/2025
Sanofi EUR 9.62B 12.23B Jun/2025
Sarepta Therapeutics USD 994.04M 52.6M Jun/2025
United Therapeutics USD 169.2M 3.8M Jun/2025
Vertex Pharmaceuticals USD 1.5B 139.6M Jun/2025